TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sensorimotor function of hemiplegic upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Functional ability of hemiplegic upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical safety of TIV vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Number and proportion of subjects reporting local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects achieving antibody responses to specific antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resting systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: frequency of target levels of HbA1c ≤ 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of drug related problems
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement of Perception of Cooling Sensation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IgG Trough Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of neonatal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Valve Thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Rate of Decline in mGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: oral glucose insulin sensitivity (OGIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in frequency of RP attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in severity of RP attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in duration of RP attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative difficulty score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: symptoms experienced
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Beta D Glucan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectral centroid (Hz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Pocket Depth (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in FIAF blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Severity and frequency of reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically-relevant changes in physical exams or laboratory testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Relapse Free Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTD (maximum tolerated dose) of BIBF 1120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Neutralizing Antibody Titer - Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: R0 resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: RNA expression levels of lncRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Learning achievement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: California Verbal Learning Test (CVLT-II - Total learning)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sensitivity and specificity of FLT-PET-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline in Minimum FCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in central sympathetic output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report of Tobacco Abstinence or Reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medical care quality in Chest Pain Units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory safety variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ART Medication Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tinnitus Reaction Questionnaire (TRQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in fetal alcohol exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percentages of nonpregnant women reporting prompted local reactions within 7 days
Endpoint domain: Adverse events/effects
Primary endpoint: Percentages of nonpregnant women reporting prompted systemic events within 7 days
Endpoint domain: Adverse events/effects
Primary endpoint: Percentages of maternal participants with each delivery outcome
Endpoint domain: Mortality/survival
Primary endpoint: Cell counts of T cells, NK cells, B cells and monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the Human Intestinal Microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Brain structural change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spinal cord change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Point-prevalent Abstinence at 4 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes of endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: executive function (memory, language and concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: executive function (selective attention, cognitive flexibility)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: executive function (visual attention and task switching)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: executive function (attention, working memory and recall verbal memory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetics of inhaled PF-00610355
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and toleration of inhaled PF-00610355
Endpoint domain: Adverse events/effects
Primary endpoint: accuracy of LSM and SSM by EUS-elastography to assess portal hypertension (PH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants That Died at 3 Months
Endpoint domain: Mortality/survival
Primary endpoint: New Venous Thromboembolism at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Correlation between toxins levels and mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Pain 6 months after surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in fear of recurrence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: metastatic lymph node involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of dental traumatic injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the score obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the score obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cravings level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in up-to-date rates for immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percent of children receiving additional vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mydriasis larger than 5.5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of photometer reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rey auditory verbal learning test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rey complex figure test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Boston naming test of 30 figures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Visual construction skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Grooved Pegboard test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Donor Graft Endothelial cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reader Agreement for Measurement Techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS (The Positive And Negative Syndrome Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Occurrence of dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Steroid-free mucosal healing (Mayo 0 or 1) at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Steroid-free clinical remission at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: TGF beta-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-mental status exam
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Modified barthel index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tinetti mobility assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Platelet Transfusion Independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentration-to-dose ratio of SSRI in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admittance to nursing home care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of children with affection of the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of PAS use for cognitive enhancement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Satisfied and Very Satisfied With Regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Opioid Usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Stone composition analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Site of stone attachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pharmacokinetics of DCV-SOF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects achieving Target Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Amount of exosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post meal sugars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptomatic outcome of GERD management
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Subjects With Acute Gastrointestinal and Genitourinary Adverse Events ≥ Grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma R406 AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma R406 Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival at 12 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients in drug free clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Other Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Activity of the Joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in MI incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of class Ⅲ or Ⅳ neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time length between HW6 administration and onset of first TS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of the EORTC QLQ-C30 Score in Cycle 1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Comparison of the EORTC QLQ-C30 Score in Cycle 2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment-related Symptoms as Assessed by PRO-CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Safety Assessment of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of Mobilization
Endpoint domain: Resource use
Primary endpoint: Change in picture naming accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients fulfilling classification criteria for inflammatory myopathies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Validity and reliability of newly developed questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KT Width at 6 Month Following Grafting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: % Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitoring of vitamin B12
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: proportion of patients being naturally decolonized from ESBL E. coli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Parent behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Child behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in sRMSdi/para/sc, RMSdi, Pdi & MIP from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: tolerability and safety of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Net whole body protein synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of perfect adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Decreased frequency of HIV related behavior
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Adverse events
Endpoint domain: Adverse events/effects
Endpoint subdomain: null
Primary endpoint: Composite Variable for Dressing Failure Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Tolerated Dose based on dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Hepatic fractional de novo lipogenesis in triglyceride rich lipoprotein (TRL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of appearance of UDP-glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of appearance of blood glucose from gluconeogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Monthly number of acute drug intake avoided
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Counts of Combined Unique Active (CUA) MRI Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnosis of pneumoconiosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: TRM (Treatment-Related Mortality)
Endpoint domain: Mortality/survival
Primary endpoint: Rate of grade II/III organ toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Manchester Scar Scale (MSS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quantitative Assessment of Scar using Patient and Observer Scar Assessment Scale (POSAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sleep breathing disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Weight-for-age Z-score at 14 Months of Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in facial pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Oral health related quality of life (OHRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Endometriosis pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Symptoms Subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ankle functional ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging Biomarkers associated with Pulmonary Embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: TOFScan recording
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Who Experienced Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Who Experienced Serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Growth Velocity (Height)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth Velocity (Weight)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiac hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptoms of chronic constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 25-OH vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in the MADRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inflammatory Cytokine Tumor Necrosis Factor Alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cerebrospinal fluid (CSF) stroke volume evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Event rate of patients with acute rejections
Endpoint domain: Adverse events/effects
Primary endpoint: Blood glucose response (incremental area under the curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin (incremental area under the curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in child asthma diagnosis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficiency of technical skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month Progression-free Survival (PFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: diagnostic sensitivity of WS technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic specificity of SNP technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma AUC0-inf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of emergency department visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rejuvenation of post burn scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of COPD exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of Solicited local reactogenicity adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Solicited systemic reactogenicity adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titer (GMT) of the serum neutralizing antibody (NAb) response to SARS-CoV-2 virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes